Clinical trial
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
NCT03375255 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 5, 2018
- Completion date
- August 19, 2019
- Enrollment
- 15 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.